Differential Co-Occurring Patterns Between Depressive Symptomatology and Sleep-Wake-Related Disturbances in Mood Disorders

Sze-Yu Chen1
Chun-Hao Chen1
Chen Lo1
Mong-Liang Lu2
Cheng-Dien Hsu3
Yi-Hang Chiu2
Chun-Hsin Chen2
Shih-Ku Lin4,5
Ming-Chyi Huang5
Hsi-Chung Chen6,1,6
Po-Hsiu Kuo1,7

1Department of Psychiatry, National Taiwan University Hospital, Taipei, Taiwan; 2Department of Psychiatry, Wan-Fang Hospital & School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; 3Department of Psychosomatic Medicine, Taiwan Adventist Hospital, Taipei, Taiwan; 4Department of Psychiatry, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan; 5Department of Psychiatry, Taipei City Hospital, Songde Branch, Taipei, Taiwan; 6Center of Sleep Disorders, National Taiwan University Hospital, Taipei, Taiwan; 7Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan

Purpose: This study aimed to elucidate the various co-occurring patterns of depressive symptomatology and sleep-wake-related disturbances (SWRDs) in patients with mood disorders.

Patients and Methods: Individuals in non-acute states of major depressive disorder or bipolar disorder were recruited. The Beck Depression Inventory II (BDI-II) was utilized to evaluate depressive symptoms. BDI-II items were classified into three domains: cognitive, affective, and somatic. Between-domain differences with various SWRDs were examined. Latent class analysis was used to empirically classify participants using BDI-II items as indicator variables. Co-occurring patterns between domains of BDI-II items and SWRDs were re-examined in each subgroup to elucidate inter-individual differences.

Results: In total, 657 participants were enrolled. Of participants, 66.8% were female, and 52.4% were diagnosed with major depressive disorder. Each BDI-II domain exhibited different co-occurring patterns. The somatic domain was most likely to co-occur with various SWRDs. Three subgroups were derived from latent class analysis and were designated as poor sleep quality and high insomnia (n=150), poor sleep quality and moderate insomnia (n=248), and poor sleep quality and low insomnia (n=159). The group with more severe insomnia presented with more severe depressive and anxiety symptoms. The three subgroups further differed in co-occurring patterns. From the low insomnia to high insomnia group, the associations with various SWRDs appeared in the sequence of somatic, affective, and cognitive domains.

Conclusion: Co-occurring patterns between domains of depressive symptomatology with various SWRDs differ and may vary among individuals.

Keywords: co-occurring, latent class analysis, mood disorders, sleep-wake-related disturbance, depression

Introduction

Mood disorders are highly prevalent.1 Of the various mood disorders, depression exhibits the highest recurrence and is characterized by chronicity. In patients with bipolar disorder, depression, rather than mania, comprises a longer duration in the disease course,2 and depressive symptoms have the greatest impact on quality of life.3 Sleep-wake-related disturbances (SWRDs) are strongly correlated with depression. More than 80% of patients with depression experience prominent insomnia.4 Further, sleep architecture in individuals with depression differs from that of healthy controls, even during the remission state.5 The bidirectional relationship between depression and SWRDs has been established. Depression may
precede complaints of insomnia,6 and insomnia may predict the new onset7 or recurrence of depression.7-9 In summary, SWRDs are considered a core symptom of depression and serve as an important factor when investigating the neurobiological mechanisms of depression.

Various neural circuits underpin depression10 and SWRDs.11 The neurobiology of sleep-wake regulation overlaps considerably with that of mood.12,13 For instance, patients with depression exhibited increased rapid eye movement (REM) sleep; this phenomenon was amplified when cholinergic neurotransmission was augmented. Healthy participants administered with cholinomimetics developed depressive symptoms including anhedonia and fatigue.5 Further, most antidepressants alter sleep architecture. Administration of selective serotonin reuptake inhibitors or monoamine oxidase inhibitors decreased the total duration of REM sleep, and a transient decrement in serotonin levels achieved by tryptophan depletion reversed this effect.14 Electroconvulsive therapy has consistently been shown to lengthen sleep duration, improve sleep efficacy, and shift REM sleep patterns to approximate those of healthy sleepers.15 In summary, depressive symptomatology and various SWRDs are closely related and may share common neurobiological pathomechanisms. An in-depth exploration of their specific co-occurring relationships may reveal shared biophysical vulnerabilities and address issues arising from the heterogeneity of depression.

Common psychometers that are used to measure depressive symptomatology include over 50 depressive symptoms.16 Thus, each domain of depression may possess diverse associations with specific SWRDs. A recent network analysis revealed different associations between the items of the Inventory of Depressive Symptomatology with insomnia. Specifically, depression was partially associated with insomnia, but irritability, anxiety, and interpersonal hypersensitivity were not directly associated with insomnia.17 Additionally, symptom profiles differ substantially between individuals diagnosed with depressive disorders.18 This phenotypic heterogeneity reflects the complex pathogenesis of depression, which hinders precise elucidation of the pathomechanisms of depression and development of precision medicine.19 Consequently, when investigating the associations between depressive symptomatology and SWRDs, individual differences in depressive symptomatology should be considered.

Thus, in the present study, the associations between depressive symptomatology and SWRDs were examined in participants diagnosed with mood disorders. First, the independent associations between each fundamental domain of depression (cognitive, affective, and somatic) and SWRDs were examined. Subsequently, with depressive symptoms as indicator variables, latent class analysis (LCA) was utilized to empirically subgroup participants. The associations between SWRDs and depressive domains were then re-examined in participants of each subgroup to elucidate individual differences.

Patients and Methods
Participants
Participants were enrolled in three general hospitals and one psychiatric hospital in Taiwan between 2013 and 2018. Individuals fulfilling all the following criteria were referred by clinicians: (a) aged between 18 and 65 years old; (b) diagnosed with major depressive disorder (MDD) or bipolar affective disorder (BAD) according to the Diagnostic and Statistical Manual of Mental Disorders (DSM) – IV; and (c) non-acute status, defined as a score less than 17 on the Hamilton Depression Rating Scale20 and less than 20 on the Young Mania Rating Scale.21 The diagnosis of MDD or BAD in eligible participants was further confirmed using the Chinese version of the Schedule for Affective Disorder and Schizophrenia-Lifetime (SADS-L).22,23 Exclusion criteria included comorbid schizophrenia, intellectual disability, and substance use disorder. Trained interviewers collected comprehensive data on sociodemographic variables (sex, age, marital status, birth location, academic attainment, employment status, and income), lifestyle factors (body mass index, exercise habit, and use of alcohol or tobacco), and history of physical illness and psychiatric conditions (psychiatric diagnosis, hypnotic use, depressive symptoms, and anxiety symptoms). This study was approved by the Institutional Review Board of the National Taiwan University Hospital (NO. 201212134RINB, 201512086RIND, and 202007094RINA). Written informed consent was obtained from each participant, and the study was conducted in accordance with the 2008 revision of the Helsinki Declaration of 1975.

Measurement and Categorization of Depressive Symptomatology
The Chinese version of the Beck Depression Inventory II (BDI-II) was used to measure and quantify depressive symptoms. The reliability and validity of the Chinese
version of BDI was examined. In terms of reliability, the Chinese version of the BDI-II has a Cronbach’s alpha of 0.94, and a split-half reliability of 0.91. Two factors were explored in the exploratory factor analysis, including the cognitive-affective and somatic dimensions. The Chinese version of the BDI-II correlates well with the Chinese Health Questionnaire (r=0.69, p<0.001), which indicates an acceptable degree of convergent validity. The criterion validity for depressive disorders, which was measured using the area under the receiver operating characteristic curve, was 0.78 ± 0.04, with an optimal cutoff of 16/17, sensitivity of 80.4%, specificity of 62.8%, and positive predictive value of 72.8%. BDI-II included 21 items: sadness (D1), pessimism (D2), past failure (D3), loss of pleasure (D4), guilty feelings (D5), punishment feelings (D6), self-dislike (D7), self-criticalness (D8), suicidal thoughts or wishes (D9), crying (D10), agitation (D11), loss of interest (D12), indecisiveness (D13), worthlessness (D14), loss of energy (D15), changes in sleep patterns (D16), irritability (D17), changes in appetite (D18), concentration difficulties (D19), tiredness or fatigue (D20), and loss of interest in sex (D21). As we aimed to investigate the associations between depressive symptoms and SWRDs, item D16 (“change in sleep patterns”) was excluded to prevent the introduction of statistical collinearity. For more relevant clinical implications, the remaining 20 items were divided into three domains based on previous literature, comprising the affective domain (D1, D4, D10, D11, D12, and D17), cognitive domain (D2, D3, D5, D6, D7, D8, D9, D13, D14, and D19), and somatic domain (D15, D18, D20, and D21), respectively. The scores of items in each domain were summed, and their respective associations with various SWRDs were examined.

Measurement of Sleep-Wake-Related Symptoms
Sleep Quality
The Pittsburgh Sleep Quality Index (PSQI) was used to measure sleep quality over the past 1 month. The PSQI comprised 19 items which encompassed seven components, including subjective sleep quality (component 1, C1), sleep onset latency (component 2, C2), total sleep duration (component 3, C3), sleep efficiency (component 4, C4), sleep disturbances (component 5, C5), use of sleep medication (component 6, C6), and daytime dysfunction (component 7, C7). Each component was assigned a score between 0 and 3, resulting in a global score of 21. The Chinese version of the PSQI has been validated, whereby a score of 6 or more indicates poor sleep quality. Because hypnotic use would confound the association between depressive symptomatology with SWRD, C6 was specified as a covariate in subsequent stratified analyses with each component score. A component score other than zero was defined such “case” in the related analyses.

Chronotype Preference
Chronotype preference was assessed using the Morningness-Eveningness questionnaire (MEQ). The MEQ is a self-report questionnaire with a total score between 13 and 55 points. Lower scores indicate a preference towards eveningness. The validity and reliability of the Chinese version of the MEQ have been established. The lowest quartile of MEQ scores was defined as eveningness preference in the present study.

Night and Daytime Symptoms of Insomnia
Sleep loss was defined as the gap between actual sleep duration and subjective evaluation of the required sleep duration for each individual. “Sleep loss” was considered a case of actual sleep duration which was 2 or more hours less than the sleep duration subjectively required by an individual. Three questions were adopted to evaluate night symptoms of insomnia: “In the past 12 months, it takes more than 2 hours almost every night to fall asleep” for sleep initiation difficulty, “Sleep interruption occurs almost every night, and it takes more than one hour to fall asleep again” for sleep maintenance difficulty, and “Being awake more than 2 hours earlier than one expected” for early morning awakening. Daytime symptoms of insomnia were evaluated using the question: “Having persistent daytime sleepiness for at least 2 weeks.” Positive responses to the aforementioned questions were defined as “cases” for respective symptoms.

Other Physical and Mental Comorbidities
History of physical illnesses was defined based on self-reports by the participants, including cardiovascular, endocrine, metabolic, gastrointestinal, urinary, hematological, infectious, neurological/musculoskeletal, and immune/asthma/allergic diseases. Anxiety symptoms were assessed using the Chinese version of the Beck Anxiety Inventory (BAI).
Statistical Analyses

SPSS for Windows, version 17.0 (SPSS, Chicago, IL) was used for most analyses. Mplus version 7 (Muthen & Muthen) was used for LCA. Univariate analysis was performed using a \( \chi^2 \) test or analysis of variance (ANOVA). Multivariable regression was used to examine the independent relationships between each depressive domain and SWRDs. The results were expressed as odds ratios (ORs) and 95% confidence. Moreover, the scores of each domain of the BDI-II, age, sex, BAI scores, psychiatric diagnosis, and hypnotic use were also specified in each logistic regression model to control for the confounding effects. P-values less than 0.05 were considered statistically significant.

Subgrouping by Latent Class Analysis

To investigate individual differences in the associations between depression domains and SWRDs, participants were empirically subgrouped by LCA. The 20 items of the BDI-II were used as indicator variables for LCA. We further conducted a subgroup-stratified analysis. The optimal number of subgroups was determined using five fitness indices for LCA. Lower values resulted from Akaike’s information criterion (AIC), and sample size-adjusted Bayesian information criterion (sBIC) indicated superior model fits. The value of entropy close to one suggested a clear classification, while a value higher than 0.7 was considered adequate. Likelihood ratio tests were implemented to compare fitness between two models. Lo-Mendell-Rubin adjusted likelihood ratio test and parametric bootstrapped likelihood ratio test were used for comparison between adjacent classes. A significant \( p \)-value was interpreted as a k class model with a superior fit to that of k-1 class model.

Results

In total, 657 participants were enrolled in the present study. Of participants, 66.8% were female, and 52.7% were over 45 years old. Of participants, 52.4% were diagnosed with MDD, and 75.7% used hypnotics. The average BDI-II score was 14.8 (Standard deviation [SD]=11.8). The average BAI score was 13.2 (SD=12.2) (Table 1).

Table 2 includes the five fitness indices for LCA models. Based on AIC and sBIC, a five-group model was superior to a four-group model or a three-group model. A three-group model had an entropy value closest to one. According to Lo-Mendell-Rubin adjusted likelihood ratio test, having five subgroups was not superior to having four groups. In both three-group model and four-group model, the major between-group difference was the mean score of BDI, which indicated different severity of depression. Because the homogeneous distribution pattern among the indicator variables and the consideration of statistical power, a three-group was favored in terms of practical utility (Figure S1). Overall, a three-group model had the best entropy value and better clinical utility; therefore, the three-group model was selected. The three subgroups were designated based on their SWRD characteristics: poor sleep quality and high insomnia (PSQ+HI, \( n=150 \)), poor sleep quality and moderate insomnia (PSQ+MI, \( n=248 \)), and poor sleep quality and low insomnia (PSQ+LI, \( n=159 \)). All three groups were termed as “poor sleep quality” to highlight that poor sleep quality was consistently prevalent across the subgroups (76.7–93.7%), which was discordant with the relatively low proportion of individuals with insomnia symptoms.

With regard to baseline characteristics, the PSQ+HI group comprised a higher proportion of females (79.3%), and the PSQ+LI group comprised a higher proportion of individuals with high income (31.8%). With regard to lifestyle factors, the PSQ+LI group comprised a higher proportion of participants participating in regular exercise (62.5%), and the PSQ+MI group comprised the least regular drinkers (11.4%). The PSQ+HI group exhibited substantially more physical comorbidities and comprised significantly more participants diagnosed with MDD and participants with hypnotics use. The PSQ+HI group exhibited the highest average BDI-II and BAI scores (Table 1).

Table 3 summarizes the SWRD profiles of all participants and the three subgroups. Of participants, 84.9% had poor sleep quality (PSQI total score ≥ 6), and 34.3% had subjective sleep loss. Each night and daytime symptom of insomnia was present in approximately one third of participants (30.3–41.0%). Between-group comparisons revealed that SWRDs were most prevalent in the PSQ+HI group, slightly less in the PSQ+MI group, and were least prevalent in the PSQ+LI group with the exception of early morning awakening and daytime sleepiness, which were distinctly more common in the PSQ+LI group than in the PSQ+MI group. Similarly, PSQI-defined poor sleep quality was evident across subgroups, ranging from 76.7% to 93.7%. Night symptoms of insomnia were lowest in the PSQ+LI group (26.9–29.0%), but daytime sleepiness was not lowest in the PSQ+LI group (43.8%).

Figure 1 illustrates the independent relationship between domains of depressive symptomatology and...
Table 1 Sociodemographic Characteristics of Participants (n=657)

|                           | Total  | PSQ+HI* | PSQ+MI | PSQ+LI | p-value for χ²/ANOVA |
|---------------------------|--------|---------|--------|--------|----------------------|
| **Sex (n, %)**            |        |         |        |        |                      |
| Female                    | 439 (66.8) | 119 (79.3) | 149 (60.1) | 175 (66.0) | <0.001              |
| Male                      | 218 (33.2) | 31 (20.7)  | 99 (39.9)  | 90 (34.0)  |                      |
| **Age (n, %)**            |        |         |        |        |                      |
| ≤30 years                 | 92 (15.9)  | 22 (17.1)  | 33 (15.4)  | 37 (15.8)  | 0.13                |
| 31–44 years               | 181 (31.4) | 49 (38.0)  | 71 (33.2)  | 61 (26.1)  |                      |
| ≥45 years                 | 304 (52.7) | 58 (45.0)  | 110 (51.4) | 136 (58.1) |                      |
| **Marital status (n, %)** |        |         |        |        |                      |
| Single                    | 217 (37.6) | 54 (41.9)  | 80 (37.4)  | 83 (35.5)  | 0.06                |
| Married                   | 251 (43.5) | 43 (33.3)  | 94 (43.9)  | 114 (48.7) |                      |
| Other                     | 109 (18.9) | 32 (24.8)  | 40 (18.7)  | 37 (15.8)  |                      |
| **Birth place (n, %)**    |        |         |        |        |                      |
| Urban                     | 450 (79.8) | 111 (86.7) | 159 (75.7) | 180 (79.6) | 0.05                |
| Rural                     | 114 (20.2) | 17 (13.3)  | 51 (24.3)  | 46 (20.4)  |                      |
| **Education (n, %)**      |        |         |        |        |                      |
| University and higher     | 271 (47.1) | 48 (37.5)  | 112 (52.3) | 111 (47.6) | 0.10                |
| Senior high school        | 205 (35.7) | 53 (41.4)  | 72 (33.6)  | 80 (34.3)  |                      |
| Junior high school and lower | 99 (17.2) | 27 (21.1)  | 30 (14.0)  | 42 (18.0)  |                      |
| **Work status (n, %)**    |        |         |        |        |                      |
| Employed                  | 221 (38.6) | 46 (35.7)  | 83 (39.3)  | 92 (39.5)  | 0.74                |
| Unemployed                | 352 (61.4) | 83 (64.3)  | 128 (60.7) | 141 (60.5) |                      |
| **Income (n, %)**         |        |         |        |        |                      |
| High (≥40,000 NTD/month)  | 157 (28.6) | 23 (19.0)  | 63 (30.7)  | 71 (31.8)  | 0.04                |
| Moderate (10,000–39,999 NTD/month) | 174 (31.7) | 45 (37.2)  | 55 (26.8)  | 74 (33.2)  |                      |
| Low (0–9999 NTD/month)    | 218 (39.7) | 53 (43.8)  | 87 (42.4)  | 78 (35.0)  |                      |
| **Body mass index (n, %)**|        |         |        |        |                      |
| Healthy weight (18.5-<24.0 kg/m²) | 305 (54.0) | 63 (50.0)  | 111 (53.1) | 131 (57.0) | 0.61                |
| Underweight (<18.5 kg/m²) | 43 (7.6)  | 11 (8.7)   | 19 (9.1)   | 13 (5.7)   |                      |
| Overweight (24.0-<27.0 kg/m²)| 155 (27.4) | 34 (27.0)  | 57 (27.3)  | 64 (27.8)  |                      |
| Obesity (≥27.0 kg/m²)     | 62 (11.0)  | 18 (14.3)  | 22 (10.5)  | 22 (9.6)   |                      |
| **Lifestyle (n, %)**      |        |         |        |        |                      |
| Regular exercise (> 2 times/week) | 312 (54.7) | 52 (40.6)  | 115 (54.8) | 145 (62.5) | <0.001              |
| Cigarette use             |         |         |        |        |                      |
| Non-smoker                | 372 (65.7) | 81 (64.8)  | 136 (64.2) | 155 (67.7) | 0.43                |
| Ex-smoker                 | 75 (13.3)  | 12 (9.6)   | 32 (15.1)  | 31 (13.5)  |                      |
| Current smoker            | 119 (21.0) | 32 (25.6)  | 44 (20.8)  | 43 (18.8)  |                      |
| Regular alcohol drinking>1 year | 96 (17.1)  | 27 (21.8)  | 26 (11.4)  | 43 (20.5)  | 0.01                |
| **Comorbid disease (n, %)**|        |         |        |        |                      |
| Cardiovascular disease    | 132 (23.2) | 23 (18.0)  | 51 (24.2)  | 58 (25.1)  | 0.28                |
| Endocrinology and metabolism disease | 164 (29.1) | 45 (35.4)  | 51 (24.4)  | 68 (30.0)  | 0.10                |
| Gastroenterology disease  | 260 (45.5) | 78 (60.9)  | 97 (45.8)  | 85 (36.6)  | <0.001              |
| Urinary system disease    | 62 (10.9)  | 17 (13.3)  | 29 (13.8)  | 16 (6.9)   | 0.04                |
| Infectious disease        | 9 (1.6)    | 1 (0.8)    | 5 (2.4)    | 3 (1.3)    | 0.47                |
| Neuromuscular disease     | 201 (35.3) | 62 (48.8)  | 78 (37.0)  | 61 (26.3)  | <0.001              |
| Autoimmune disease/asthma and allergy | 166 (29.0) | 39 (30.5)  | 63 (29.7)  | 64 (27.6)  | 0.81                |

(Continued)
Table 1 (Continued).

|                          | Total  | PSQ+HI* | PSQ+MI | PSQ+LI | p-value for χ²/ANOVA |
|--------------------------|--------|---------|--------|--------|----------------------|
| n=657                    | 83 (14.5) | 23 (18.0) | 31 (14.7) | 29 (12.5) | 0.37 |
| Hematologic disease      |        |         |        |        |                      |
| Psychiatric diagnosis    |        |         |        |        |                      |
| n, %                     |        |         |        |        |                      |
| Bipolar affective disorder | 313 (47.6) | 55 (36.7) | 103 (41.5) | 155 (59.8) | <0.001 |
| Major depressive disorder | 344 (52.4) | 95 (63.3) | 145 (58.5) | 104 (40.2) |          |
| Use of psychotropic agents, n, % |        |         |        |        |                      |
| Antidepressants          | 358 (54.8) | 107 (72.3) | 145 (58.9) | 106 (40.9) | <0.001 |
| Mood stabilizers         | 239 (36.5) | 39 (26.2) | 78 (31.7) | 122 (47.1) | <0.001 |
| Antipsychotics           | 264 (40.4) | 71 (47.7) | 94 (38.2) | 99 (38.2) | 0.12 |
| Hypnotics use            | 432 (75.7) | 111 (88.1) | 163 (76.5) | 158 (68.1) | <0.001 |
| Beck Depression Inventory-II [mean (SD)] | 14.8 (11.8) | 31.8 (5.1) | 16.3 (6.1) | 3.5 (2.9) | <0.001 |
| Beck Anxiety Inventory [mean (SD)] | 13.2 (12.2) | 26.1 (11.4) | 13.3 (12.2) | 6.1 (7.4) | <0.001 |

Abbreviations: *PSQ, poor sleep quality; HI, high insomnia; MI, moderate insomnia; LI, low insomnia; SD, standard deviation.

Table 2 Model Fitting Results for 3- to 5-Class Solutions in the Latent Class Analysis (n=657)

|                        | 3 Classes | 4 Classes | 5 Classes |
|------------------------|-----------|-----------|-----------|
| Akaike Information Criterion | 20,533.92 | 20,178.22 | 20,025.83 |
| Sample-Size Adjusted Bayesian Information Criterion | 20,694.07 | 20,392.19 | 20,293.62 |
| Entropy                | 0.93      | 0.91      | 0.91      |
| Lo-Mendell-Rubin Adjusted Likelihood Ratio test | 0.0046 | 0.0002 | 0.6234 |
| Parametric Bootstrapped Likelihood Ratio test | <0.0001 | <0.0001 | <0.0001 |

Table 3 Univariate Analysis for Sleep-Wake-Related Disturbances in Subgroups (n=657)

|                      | Total  | PSQ+HI* | PSQ+MI | PSQ+LI | p-value for χ²/ANOVA |
|----------------------|--------|---------|--------|--------|----------------------|
| n=657                | 485 (84.9) | 118 (93.7) | 189 (88.7) | 178 (76.7) | <0.001 |
| Hematologic disease  |        |         |        |        |                      |
| Psychiatric diagnosis |        |         |        |        |                      |
| n, %                 |        |         |        |        |                      |
| Subjective sleep     | 245 (42.9) | 84 (66.7) | 98 (46.0) | 63 (27.2) | <0.001 |
| Sleep latency        | 314 (55.0) | 86 (68.3) | 116 (54.5) | 112 (48.3) | 0.001 |
| Sleep duration       | 119 (20.8) | 40 (31.7) | 40 (18.8) | 39 (16.8) | 0.003 |
| Sleep efficiency     | 125 (21.9) | 41 (32.5) | 42 (19.7) | 42 (18.1) | 0.004 |
| Sleep disturbance    | 448 (78.5) | 105 (83.3) | 173 (81.2) | 170 (73.3) | 0.04 |
| Daytime dysfunction  | 162 (28.4) | 63 (50.0) | 61 (28.6) | 38 (16.4) | <0.001 |
| Eveningness chronotype, n, % | 126 (26.1) | 45 (42.9) | 55 (29.6) | 26 (13.6) | <0.001 |
| Subjective sleep loss | 177 (34.3) | 49 (44.5) | 70 (36.8) | 58 (26.9) | 0.004 |
| Sleep initiation difficulty, n, % | 203 (35.9) | 54 (43.5) | 81 (38.6) | 68 (29.3) | 0.02 |
| Sleep maintenance difficulty, n, % | 207 (36.6) | 64 (51.6) | 76 (36.2) | 67 (28.9) | <0.001 |
| Early morning awakening, n, % | 171 (30.3) | 52 (41.9) | 58 (25.1) | 61 (29.0) | 0.004 |
| Daytime sleepiness, n, % | 231 (41.0) | 63 (50.8) | 76 (33.2) | 92 (43.8) | 0.003 |

Abbreviations: *PSQ, poor sleep quality; HI, high insomnia; MI, moderate insomnia; LI, low insomnia.
PSQI-defined poor sleep quality and six components in all participants and each subgroup. The results of multiple logistic regression analyses are detailed in Supplement Table S1. Of participants, daytime dysfunction was the only component related to all three domains of depression (panel A). In subgroup analyses, additional co-occurring patterns were observed in specific subgroups. In the PSQ+HI group, cognitive and affective domains were related to sleep latency and efficiency, respectively (panel B). Figure 2 depicts the independent relationship between domains of depressive symptomatology with chronotype preference and insomnia symptoms. The results of multiple logistic regression analyses are presented in Supplement Table S2. Cognitive and somatic domains were more likely to co-occur with evening chronotype, while the somatic domain was additionally related to subjective sleep loss (panel A). Among the subgroups, the PSQ+HI group contained the highest number of co-occurring associations. Despite a null association when analyzing total participants, sleep initiation difficulties were specifically related to the cognitive domain in the PSQ+HI group (panel B) and to the affective domain in the PSQ+MI group (panel C). In the PSQ+HI group, the somatic domain was related to early morning awakening and daytime sleepiness (panel B); these associations were only identified in the subgroup analyses.

Integration of the identified co-occurring patterns revealed that depressive symptomatology exhibited various co-occurring patterns with SWRDs. In general, the somatic domain exhibited the highest number of associations with SWRDs. When comparing co-occurring patterns in each subgroup, a progressive order was noted (Figure S2). In the order of PSQ+LI, PSQ+MI, and PSQ+HI groups, the co-occurring associations between various SWRDs and
domains of depressive symptomatology appeared in the sequence of somatic, affective, and cognitive domains.

**Discussion**

This study aimed to elucidate the complex associations between depressive symptomatology and SWRDs in individuals with mood disorders. To this end, we categorized depressive symptomatology into three domains and further empirically subgrouped participants to disentangle the heterogeneity of depressive symptomatology between individuals. Our findings indicate that even in the non-acute state, a large proportion of participants still presented with SWRDs. In addition, the three domains of depression exhibited different co-occurring patterns with SWRDs, and these patterns further varied in empirically derived subgroups.

Although there is abundant literature on the heterogeneity of depression based on LCA, to the best of our knowledge, the present study is the first to recruit only participants with a non-acute state of depression. In a systematic review that included 24 articles using LCA to identify depression subgroups, half of the articles were based on community populations, and the other half was based on clinical populations. Most of the clinical samples focused on the acute state of mood disorders, and the others examined cohorts comprising both acute and non-acute state patients. Compared to individuals in the acute state, those in the non-acute state are more likely to reflect long-term trait-like psychopathology which may indicate underlying neurophysiological pathomechanisms. Further, only one previous study that also used LCA to subgroup depression addressed the associations between depression symptoms with night symptoms of insomnia. Thus, the analytical strategy, characteristics of participants, and various types of SWRDs are unique features of the present study.

**Rationale for Classifying BDI-II Depressive Symptoms**

In the present study, depressive symptoms of the BDI-II were empirically assigned to three domains. This conceptual

![Image](https://www.example.com/image.png)

**Figure 2** The co-occurring patterns between domains of depressive symptomatology with various nighttime and daytime symptoms of insomnia and chronotype preferences. C: cognitive domain; A: affective domain; S: somatic domain. The number (odds ratio) and thickness of the lines linking each domain and PSQI-related components reflect the effect sizes of associations. The co-occurring patterns are illustrated by participant groups. Panel (A): total participants. Panel (B): the poor sleep quality with high insomnia (PSQ+HI) group. Panel (C): the poor sleep quality with moderate insomnia (PSQ+MI) group. Panel (D): the poor sleep quality with low insomnia (PSQ+LI) group.
Dovepress

Chen et al

Differential Co-Occurring Patterns Between Domains of Depressive Symptomatology and SWRDs

Of the three domains, the somatic domain was most likely to be associated with various nighttime symptoms of SWRDs. This finding agrees with previous reports of factor analysis indicating that sleep-related items were almost always classified into similar factors as symptoms of loss of energy, change in appetite, or interest in sex. In this study, this finding also suggests a shared pathomechanism involving the hypothalamus, which maintains fundamental physiological demands, such as sleep, appetite, and sex.

In contrast to previous research on nighttime symptoms of SWRDs and mood disorders, the present study highlighted the importance of addressing daytime manifestations of SWRDs. In this study, the prevalence of daytime sleepiness, which was defined as daytime symptoms of insomnia, was high in all participants (41%) and higher than that in the general population (1.0–6.4%). Furthermore, PSQI-defined daytime dysfunction co-occurred with all domains of depression in all participants. This consistent co-occurring pattern across domains echoes previous arguments that daytime symptoms of insomnia are more strongly correlated with depressive symptomatology when compared to nighttime symptoms. Daytime SWRDs may indicate residual symptoms of depression, suboptimal treatment of SWRDs, or adverse effects from psychotropic agents. Further investigations of the prevalence of daytime SWRDs in individuals with non-acute mood disorders are warranted.

Another notable finding of the present study was the co-occurring pattern of the eveningness chronotype and the cognitive and somatic domains of depressive symptomatology. This finding is consistent with previous reports that inpatients with mood disorders and eveningness preference had higher scores in the cognitive and somatic domains of the BDI-II. Several mechanisms may underpin the link between the cognitive domain and eveningness preference. First, the eveningness chronotype is associated with suicidal behavior. Second, the CLOCK gene rs1801260 C allele is correlated with both eveningness preference and hopelessness, which is a psychopathology under the umbrella of pessimism. Since both suicidal ideation and pessimism are cognitive symptoms of the BDI-II, our findings suggest a similar phenomenon.

In the present study, the somatic domain included four items of the BDI-II including loss of energy, changes in appetite, tiredness or fatigue, and loss of interest in sex. These symptoms are at least partly controlled by the arousal system and/or reward system in the central nervous system. The neural substrate underpinning the co-occurring evening preference and somatic domain of depressive symptomatology may be the hypothalamus, which regulates circadian rhythmicity and modulates arousal and reward systems. In addition, this co-occurring pattern may also be due to a misalignment between inner circadian rhythms and external social rhythms.

Differential Co-Occurring Patterns Between Depressive Symptomatology and SWRDs Among Subgroups

In this study, we used LCA to identify subgroups with homogeneous profiles of the BDI-II symptomatology. Among the three subgroups, differential co-occurring patterns were observed. This finding suggests distinct pathomechanisms and clinical implications. First, in the order of PSQ+LI, PSQ+MI, and PSQ+HI, the corresponding sequence of specific domains of depressive symptomatology co-occurring with any SWRD was somatic, affective, and cognitive. As these three subgroups differed in the overall severity of depressive symptoms, our findings suggest that in some subgroups of patients, cognitive therapy for both SWRDs and depressive symptoms may be beneficial, such as in the PSQ+HI group. In contrast, somatic or behavioral treatments may be the most effective intervention in other circumstances, such as in the PSQ+LI group. Second, the
co-occurring patterns that were only identified in subgroup analysis warrant further attention. For example, sleep initiation difficulties and PSQI-defined prolonged sleep latency co-occurred with specific domains in the subgroup analyses but not in analyses that used the entire sample. Statistically, co-occurring patterns that were identified using the total sample but failed to appear in subsequent stratified analyses could be interpreted as inadequate statistical power in each subgroup analysis. In contrast, the identification of co-occurring patterns only in specific subgroups suggested that differential strength of co-occurring patterns between subgroups nullifies an association that should appear in a specific subgroup. For example, the co-occurring pattern for depressive domains with sleep initiation difficulties was uniquely identified in the PSQ+HI and PSQ+HI subgroups. Notably, sleep initiation difficulties co-occurred with the cognitive domain in the PSQ+HI subgroup and with the affective domain in the PSQ+MI subgroup. This group-specific association hints at different pathomechanisms underlying similar SWRD phenotypes in individuals with non-acute state mood disorders. As insomnia is formulated as a consequence of hyperarousal (cognitive, affective, and somatic) in modern insomnia theoretical models,\textsuperscript{58,59} cognition-related hyperarousal in the PSQ+HI group and affect-related hyperarousal in the PSQ+LI group may differentially explain an identical insomnia phenotype that requires distinct interventions.

Limitations
This study has several limitations. First, this was a cross-sectional study; therefore, causal inferences could not be drawn. Second, multiple comparisons in a series of logistic regression analyses may have inflated type I errors. Furthermore, psychotropic agents other than hypnotics may have introduced additional confounding effects. Third, participants in this study were from mixed samples of MDD and BAD, for which the pathomechanisms for depressive symptomatology may differ in essence. However, we controlled for psychiatric diagnosis in the multiple logistic regression analyses. Therefore, the potential confound from diagnosis was at least partly mitigated. Fourth, this study did not include a healthy control group, which may provide additional insight into the clinical implications of the results. Finally, although depressive symptoms in the BDI-II were categorized into three domains, it remains unclear whether all symptoms in a specific domain could be ascribed to a common neurobiological pathomechanism regardless of whether the classification was performed empirically or by factor analysis.

Conclusions
SWRDs provide an important window into the biological basis of depressive symptoms. Our findings support the arguments of diverse neurophysiological pathogenesis in depressive disorders and hint at neurophysiological targets in specific subgroups of patients in terms of investigation of pathomechanisms or clinical interventions. The new paradigm of “co-occurrence/co-existence” has been proposed to replace traditional primary-secondary concepts in most recent diagnostic systems to conceptualize co-occurring depressive disorders with insomnia disorders. In parallel, the clinical guidelines for insomnia inform clinicians regarding the simultaneous management of insomnia and co-occurring morbidities. However, tailored interventions for individuals with these co-occurring conditions are lacking. The present study suggests a novel strategy to disentangle heterogeneous etiologies in individuals with depressive disorder. In the future, studies using functional neuroimaging or interventions that target specific brain areas are necessary to validate the shared biological substrates for these co-occurring patterns.

Abbreviations
AIC, Akaike’s information criterion; AOR, adjusted odds ratio; BAD, bipolar affective disorder; BAI, Beck Anxiety Inventory; BDI-II, Beck Depression Inventory II; DSM, Diagnostic and Statistical Manual of Mental Disorders; LCA, latent class analysis; MDD, major depressive disorder; MEQ, Morningness-Eveningness questionnaire; PSQI, Pittsburgh Sleep Quality Index; PSQ+HI, poor sleep quality and high insomnia; PSQ+LI, poor sleep quality and low insomnia; PSQ+MI, poor sleep quality and moderate insomnia; REM, rapid eye movement; SADS-L, Schedule for Affective Disorder and Schizophrenia-Lifetime; SD, standard deviation; sBIC, sample-size adjusted Bayesian’s information criterion; SWRD, Sleep-wake-related disturbances.

Data Sharing Statement
All data and materials related to the study can be obtained by contacting the corresponding author.

Author Contributions
All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation,
or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

**Funding**
Participants were supported by National Taiwan University Hospital grant (UN110-021), Taiwan Ministry of Science and Technology (MOST) grants (105-2628-B-002-028-MY3, 108-2314-B-002-110-MY2, and 108-2314-B-002-136-MY3) and a grant from National Health Research Institute (NHRI-EX108-10627NI). The sponsor has no role in any of the stages from study design to submission of the paper for publication.

**Disclosure**
Financial competing interests: none.
Non-financial competing interests: none.

**References**

1. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2018;392 (10159):1789–1858.

2. Post RM, Denicoff KD, Leverich GS, et al. Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. *J Clin Psychiatry*. 2003;64(6):680–690. doi:10.4088/JCP.v64n0610

3. Gao K, Su M, Sweet J, Calabrese JR. Correlation between depression/anxiety symptom severity and quality of life in patients with major depressive disorder or bipolar disorder. *J Affect Disord*. 2019;244:9–15. doi:10.1016/j.jad.2018.09.063

4. Geoffroy PA, Hoertel N, Etain B, et al. Insomnia and hypersomnia in major depressive episode: prevalence, sociodemographic characteristics and psychiatric comorbidity in a population-based study. *J Affect Disord*. 2018;226:132–141. doi:10.1016/j.jad.2017.09.032

5. Palagini L, Baglioni C, Ciapparelli A, Gemignani A, Riemann D. REM sleep dysregulation in depression: state of the art. *Sleep Med Rev*. 2013;17(5):377–390. doi:10.1016/j.smrv.2012.11.001

6. Jansson-Frojmark M, Lindblom K. A bidirectional relationship between anxiety and depression, and insomnia? A prospective study in the general population. *J Psychosom Res*. 2008;64(4):443–449. doi:10.1016/j.jpsychores.2007.10.016

7. Dombrovskiy AV, Mushant BH, Houck PR, et al. Residual symptoms and recurrence during maintenance treatment of late-life depression. *J Affect Disord*. 2007;103(1–3):77–82. doi:10.1016/j.jad.2007.01.020

8. Dombrovskiy AV, Cyranowski JM, Mushant BH, et al. Which symptoms predict recurrence of depression in women treated with maintenance interpersonal psychotherapy? *Depression and Anxiety*. 2008;25 (12):1060–1066. doi:10.1002/da.20467

9. Sivertsen B, Salo P, Myklethun A, et al. The bidirectional association between depression and insomnia: the HUNT study. *Psychosom Med*. 2012;74(7):758–765. doi:10.1097/PSY.0b013e3182648619

10. Krishnan V, Nestler EJ. Linking molecules to mood: new insight into the biology of depression. *Am J Psychiatry*. 2010;167 (11):1305–1320. doi:10.1176/appi.ajp.2009.10030434

11. Joiner WJ. The Neurobiological Basis of Sleep and Sleep Disorders. *Physiology*. 2018;33(5):317–327. doi:10.1152/physiol.00013.2018

12. Saper CB, Cano G, Seamnell TE. Homeostatic, circadian, and emotional regulation of sleep. *J Comp Neurol*. 2005;493(1):92–98. doi:10.1002/cne.20770

13. Gehman PR, Meltzer LJ, Moore M, et al. Heritability of insomnia symptoms in youth and their relationship to depression and anxiety. *Sleep*. 2011;34(12):1641–1646. doi:10.5656/sleep.1424

14. Landolt HP, Kelsoe JR, Rapaport MH, Gillin JC. Rapid tryptophan depletion reverses phenelzine-induced suppression of REM sleep. *J Sleep Res*. 2003;12(1):13–18. doi:10.1046/j.1365-2683.2003.00336.x

15. McCall WV, Rosenquist PB. Letter to the editor: the effect of ECT on sleep—a comment to Winkler et al. *J Psychiatr Res*. 2015;61:239–240. doi:10.1016/j.jpsychires.2014.10.008

16. Fried EI. The 52 symptoms of major depression: lack of content overlap among seven common depression scales. *J Affect Disord*. 2017;208:191–197. doi:10.1016/j.jad.2016.10.019

17. Fried EI, von Stockert S, Haslbeck JMB, Lamers F, Schoevers RA, Penninx BWJH. Using network analysis to examine links between individual depressive symptoms, inflammatory markers, and covariates. *Psychol Med*. 2019;1–9.

18. Fried EI, Nesse RM. Depression is not a consistent syndrome: an investigation of unique symptom patterns in the STAR*D study. *J Affect Disord*. 2015;172:96–102. doi:10.1016/j.jad.2014.10.010

19. Fried EI. Moving forward: how depression heterogeneity hinders progress in treatment and research. *Expert Rev Neurother*. 2017;17 (5):423–425. doi:10.1080/14737574.2017.1307737

20. Zimmerman M, Martinez JH, Young D, Chelminski I, Dalrymple K. Severity classification on the Hamilton Depression Rating Scale. *J Affect Disord*. 2013;150(2):384–388. doi:10.1016/j.jad.2013.04.028

21. Young RC, Fau-Biggs JT, Biggs JT, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. *Br J Psychiatry*. 1978;133 (5):429–435. doi:10.1192/bjp.133.5.429

22. Endicott J, Spitzer RL. A diagnostic interview: the schedule for affective disorders and schizophrenia. *Arch Gen Psychiatry*. 1978;35(7):837–844. doi:10.1001/archpsyc.1978.01770310043002

23. Huang SY, Lin WW, Ko HC, et al. Possible interaction of alcohol dehydrogenase and aldehyde dehydrogenase genes with the dopamine D2 receptor gene in anxiety-depressive alcohol dependence. *Alcohol Clin Exp Res*. 2004;28(3):374–384. doi:10.1097/01.ALC.0000117832.62901.61

24. Lu ML, Che HH, Chang SW, Shen WN. Reliability and Validity of the Chinese Version of the Beck Depression Inventory-II. *Taiwanese J Psychiatry*. 2002;16(4):301–310.

25. Vanheule S, Desmet M, Groenwynck H, Rosseel Y, Fontaine J. The factor structure of the Beck Depression Inventory-II: an evaluation. *Assessment*. 2008;15(2):177–187. doi:10.1177/1073191107311261

26. Manian N, Schmidt E, Bornstein MH, Martinez P. Factor structure and clinical utility of BDI-II factor scores in postpartum women. *J Affect Disord*. 2013;149(1–3):259–268. doi:10.1016/j.jad.2013.01.039

27. Garcia-Batista ZE, Guerra-Pena K, Cano-Vindel A, Herrera-Martinez SX, Medrano LA. Validity and reliability of the Beck Depression Inventory (BDI-II) in general and hospital population of Dominican Republic. *PloS One*. 2018;13(6):e0199750. doi:10.1371/journal.pone.0199750

28. Buyse DJ, Reynolds CF, Monk TH, Berman SR, Kupper DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. *Psychiatry Res*. 1989;28(2):193–213. doi:10.1016/0165-1781(89)90047-4

29. Tsai PS, Wang SY, Wang MY, et al. Psychometric evaluation of the Chinese version of the Pittsburgh Sleep Quality Index (CPSQI) in primary insomnia and control subjects. *Quality Life Res*. 2005;14 (8):1943–1952. doi:10.1007/s11136-005-4346-x
30. Smith CS, Reilly C, Midkiff K. Evaluation of three circadian rhythm questionnaires with suggestions for an improved measure of morningness. J Appl Psychol. 1989;74(5):728–738. doi:10.1037/0021-9010.74.5.728
31. Gau SS, Merikangas KR. Similarities and differences in sleep-wake patterns among adults and their children. Sleep. 2004;27(2):299–304. doi:10.1093/睡/27.2.299
32. Che-H-L, Lu M-L, Chen H-C, Chang S-W, Lee Y-J. Validation of the Chinese Version of the Beck Anxiety Inventory. Formosan J Med. 2006;10(4):447–454.
33. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988;56(6):893–897. doi:10.1037/0022-006X.56.6.893
34. Muthén LK, Muthén BO. Mplus User’s Guide. Seventh ed. Los Angeles: CA: Muthén & Muthén; 2015.
35. Akaie H. Factor analysis and AIC. Psychometrika. 1987;52(3):317–332. doi:10.1007/BF02294359
36. Selove SL. Application of model-selection criteria to some problems in multivariate analysis. Psychometrika. 1987;52(3):333–343. doi:10.1007/BF02294360
37. Celeux G, Soromenho G. An entropy criterion for assessing the number of clusters in a mixture model. J Classification. 1996;13(2):195–212. doi:10.1007/BF02214698
38. Bower K, Lynch KG, Nogin DS. Modeling Uncertainty in Latent Class Membership: a Case Study in Criminology. J Am Stat Assoc. 1999;94(447):766–776. doi:10.1080/01621459.1999.10474179
39. Tsai HC, Lu MK, Yang YK, et al. Empirically derived subgroups of bipolar I patients with different comorbidity patterns of anxiety and substance use disorders in Han Chinese population. J Affect Disord. 2012;136(1–2):81–89. doi:10.1016/j.jad.2011.08.015
40. Ulbricht CM, Chrysanthopoulou SA, Levin L, Lapane KL. The use of latent class analysis for identifying subtypes of depression: a systematic review. Psychiatr Res. 2018;266:228–246. doi:10.1016/j.psychres.2018.03.003
41. Ulbricht CM, Rothschild AJ, Lapane KL. The association between latent depression subtypes and remission after treatment with citalopram: a latent class analysis with distal outcome. J Affect Disord. 2015;188:270–277. doi:10.1016/j.jad.2015.08.039
42. Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory-II. San Antonio: Psychological Corporation; 1996.
43. Osman A, Downs WR, Barrios FX, Kopper BA, Gutierrez PM, Chiros CE. Factor structure and psychometric characteristics of the beck depression inventory-II. J Psychopathol Behav Assess. 1997;19(4):359–376. doi:10.1007/BF0229026
44. Byrne BM, Stewart SM, Lee PWH. Validating the Beck Depression Inventory-II for Hong Kong Community Adolescents. Int J Testing. 2004;4(3):199–216. doi:10.1207/s15327574iijt0403_1
45. Vanderah TW, Gould DJ. Noite’s The Human Brain: An Introduction to Its Functional Anatomy. Eighth ed. ed, Elsevier; 2021.
46. Kao CC, Huang CJ, Wang MY, Tsai PS. Insomnia: prevalence and its impact on excessive daytime sleepiness and psychological well-being in the adult Taiwanese population. Quality Life Res. 2008;17(8):1073–1080. doi:10.1007/s11136-008-9383-9
47. Koffel E, Watson D. The two-factor structure of sleep complaints and its relation to depression and anxiety. J Affect Biol Psychiatry. 2009;118(1):183–194. doi:10.1007/s0013945
48. Lai H-C, Hsu N-W, Chou P, Chen H-C. The associations between various sleep-wake disturbances and depression in community-dwelling older adults- the Yilan study. Taiwan. Aging Ment Health. 2020;24(5):717–724. doi:10.1080/13607863.2019.1582006
49. Muller MJ, Olschinski C, Kundermann B, Cabanel N. Patterns of self-reported depressive symptoms in relation to morningness-eveningness in inpatients with a depressive disorder. Psychiatry Res. 2016;239:163–168. doi:10.1016/j.psychres.2016.03.018
50. Rumble ME, Dickson D, McCall WJ, et al. The relationship of person-specific evenness chronotype, greater seasonality, and less rhythmicity to suicidal behavior: a literature review. J Affect Disord. 2018;227:721–730. doi:10.1016/j.jad.2017.11.078
51. Katzenberg D, Young T, Finn L, et al. A CLOCK polymorphism associated with human diurnal preference. Sleep. 1998;21(6):569–576. doi:10.1093/睡/21.6.569
52. Suzuki M, Dallaspezia S, Locatelli C, et al. CLOCK gene variants associated with the discrepancy between subjective and objective severity in bipolar depression. J Affect Disord. 2017;210:14–18. doi:10.1016/j.jad.2016.12.007
53. Harrington ME. Neurobiological studies of fatigue. Prog Neurobiol. 2012;99(2):93–105. doi:10.1016/j.pneurobiol.2012.07.004
54. Parekh PK, McClung CA. Circadian Mechanisms Underlying Reward-Related Neurophysiology and Synaptic Plasticity. Front Psychiatry. 2015;6:187. doi:10.3389/fpsyg.2015.00187
55. Aston-Jones G, Smith RJ, Moorman DE, Richardson KA. Role of lateral hypothalamic orexin neurons in reward processing and addiction. Neuropharmacology. 2009;56(Suppl 1):112–121. doi:10.1016/j.neuropharm.2008.06.060
56. Levandovski R, Dantus G, Fernandez LC, et al. Depression scores associate with chronotype and social jetlag in a rural population. Chronobiol Int. 2011;28(9):771–778. doi:10.3109/07420528.2011.602445
57. Wittmann M, Dinich J, Merrow M, Roenneberg T. Social jetlag: misalignment of biological and social time. Chronobiol Int. 2006;23(1–2):497–509. doi:10.1080/07420520500545979
58. Lundh LG, Broman JE. Insomnia as an interaction between sleep-interfering and sleep-interpreting processes. J Psychosom Res. 2000;49(5):299–310. doi:10.1016/S0033-2917(00)01051-0
59. Perlis ML, Giles DE, Mendelson WB, Bootzin RR, Wyatt JK. Psychophysiological insomnia: the behavioural model and a neurocognitive perspective. J Sleep Res. 1997;6(3):179–188. doi:10.1046/j.1365-2869.1997.00045.x

Nature of Science of Sleep

Publish your work in this journal

Nature of Science of Sleep is an international, peer-reviewed, open access journal covering all aspects of sleep science and sleep medicine, including the neurophysiology and functions of sleep, the genetics of sleep, sleep and society, biological rhythms, dreaming, sleep disorders and therapy, and strategies to optimize healthy sleep.

Submit your manuscript here: https://www.dovepress.com/nature-and-science-of-sleep-journal

Dovepress

Nature of Science of Sleep 2021:13